ASCO Welcomes Tobacco Bill

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

The American Society of Clinical Oncology (ASCO) is backing legislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislation explicitly states that nicotine should be

The American Society of Clinical Oncology (ASCO) is backinglegislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislationexplicitly states that nicotine should be regulated as a drug, and tobaccoproducts as drug delivery devices. The legislation also gives the FDA theauthority to regulate tobacco product advertising and promotion. Reps. GregGanske (R-Iowa), John Dingell (D-Mich), and Henry Waxman (D-Calif) are theprimary sponsors.

"We greatly appreciate the consistent leadership Reps.Ganske, Dingell, and Waxman provide on behalf of the federal regulation oftobacco products," said an ASCO statement. "Smoking accounts for atleast 30% of all cancer deaths, is a major cause of heart disease, and isassociated with conditions ranging from colds and gastric ulcers to chronicbronchitis, emphysema, and cerebrovascular disease."

Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
Related Content